Related Experiment Video
Updated: Jul 18, 2026

10:38
Culturing of Human Nasal Epithelial Cells at the Air Liquid Interface
Published on: October 8, 2013
37.0K
TBHQ Alleviates Particulate Matter-Induced Pyroptosis in Human Nasal Epithelial Cells
Ji-Sun Kim1, Hyunsu Choi2, Jeong-Min Oh2
1Department of Otorhinolaryngology Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Toxics
|June 26, 2024
Summary
Tert-butylhydroquinone (tBHQ) may treat sinonasal diseases caused by particulate matter (PM). tBHQ inhibits PM-induced pyroptosis via the Nrf2 pathway, offering a potential therapeutic strategy.
Area of Science:
- Cellular Biology
- Toxicology
- Immunology
Background:
- Pyroptosis is a pro-inflammatory cell death mechanism crucial in diseases linked to particulate matter (PM) exposure.
- The NLRP3 inflammasome pathway is a key mediator of PM-induced pyroptosis.
- Sinonasal diseases can result from PM exposure, necessitating therapeutic interventions.
Purpose of the Study:
- To investigate the therapeutic potential of tert-butylhydroquinone (tBHQ) in mitigating PM-induced sinonasal inflammation.
- To elucidate the role of the NLRP3 inflammasome and Nrf2 pathway in tBHQ's protective effects.
Main Methods:
- Western blot and ELISA were used to confirm PM-induced pyroptosis and measure IL-1β and IL-18 levels.
- Immunofluorescence and Western blot assessed tBHQ's inhibitory effects on pyroptosis.
- Nrf2 knockdown experiments were performed to determine pathway involvement.
Main Results:
- PM exposure triggered NLRP3 inflammasome-dependent pyroptosis in RPMI 2650 cells.
- tBHQ significantly inhibited PM-induced pyroptosis.
- The inhibitory effect of tBHQ was dependent on the Nrf2 pathway, as Nrf2 knockdown abolished the effect.
Conclusions:
- tBHQ demonstrates potential as a therapeutic agent for PM-induced sinonasal diseases.
- tBHQ suppresses NLRP3 inflammasome activation through the Nrf2-dependent antioxidant pathway.
- Targeting the Nrf2 pathway may be a viable strategy for managing PM-related sinonasal conditions.

